Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed $16.5B acquisition of Catalent (CTLT), Reuters’ Foo Yun Chee and Maggie Fick report, citing a person with direct knowledge of the matter. Another source told Reuters that Catalent is preparing senior management for the takeover to go through.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO: